Filing Details

Accession Number:
0001104659-19-047186
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2019-08-23 20:14:02
Reporting Period:
2019-08-20
Accepted Time:
2019-08-23 20:14:02
Original Submission Date:
2019-08-22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc. ICPT () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253170 Srinivas Akkaraju C/o Intercept Pharmaceuticals, Inc.
10 Hudson Yards, Floor 37
New York NY 10001
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-20 37,604 $65.85 368,301 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-08-21 29,000 $67.12 397,301 No 4 P Indirect See footnote
Common Stock Acquisiton 2019-08-22 1,180 $64.30 398,481 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 21,526 Direct
Footnotes
  1. These purchases were executed in multiple trades at prices ranging from $65.80 to $66.15. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  2. Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein.
  3. These purchases were executed in multiple trades at prices ranging from $66.73 to $67.53. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
  4. These purchases were executed in multiple trades at prices ranging from $64.295 to $64.30. The price reported above reflects the weighted average purchase price. Mr. Akkaraju hereby undertakes to provide full information regarding the number of shares and prices at which these purchases were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.